LIBERTY Robotic System Wins Israeli Approval, Paving Way for Global Sales
MBOT is trading near its 52-week low of $1.6 (9.2% above the low).
Summary
Microbot Medical secured Israeli AMAR regulatory approval to market its LIBERTY Endovascular Robotic System. This marks the second jurisdiction, and first outside the U.S., to grant marketing clearance for LIBERTY. The approval also enables the company to obtain a Free Sale Certificate, supporting submissions in other international markets. This is a significant step in the company's commercialization strategy, building on recent U.S. market momentum and clinical validation. The company is targeting CE Mark certification by the end of 2026 for further EU expansion.
At the time of this announcement, MBOT was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.9M. The 52-week trading range was $1.60 to $4.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.